Abstract
Second-generation antipsychotics have been found to increase a patient's risk of dyslipidemia. Despite consensus statement recommendations for lipid monitoring, studies indicate that up to 90% of patients still do not have a baseline lipid panel prior to prescription of a second-generation antipsychotic. This study retrospectively examined the prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index psychiatric hospitalization at Duke University Hospital between July 1, 2005, and July 1, 2010. Seventy patients were included in the study, with a mean age of 21.5±2.5 years. Of these patients, 22 (31.4%) had baseline lipid panels drawn during hospitalization. Lipid monitoring was statistically more frequent in males than in females (P=.01). Although not statistically significant, lipid monitoring was also more likely to occur among subjects who were African American (40%; P=.07) and with the prescription of olanzapine (50%; P=.07). About half of baseline lipid panels demonstrated either a low high-density lipoprotein or high triglycerides, indicating at least one risk factor for the metabolic syndrome. This study provides alarming evidence that, even in an academic setting ...Continue Reading
References
Sep 9, 2000·Schizophrenia Research·U OsbyP Sparén
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Feb 26, 2004·Obesity Research·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity
Aug 3, 2004·The American Journal of Psychiatry·Stephen R MarderSteven Shon
Sep 3, 2005·Schizophrenia Research·Joseph P McEvoyJeffrey A Lieberman
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·Schizophrenia Research·Donald C GoffJeffrey A Lieberman
Mar 30, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·C InvittiG C Viberti
Apr 8, 2006·Psychopharmacology·Ren-Rong WuJing-Song Tang
Oct 18, 2007·JAMA : the Journal of the American Medical Association·John W Newcomer, Charles H Hennekens
Dec 7, 2007·The Journal of Clinical Psychiatry·Rocio Perez-IglesiasJose Luis Vazquez-Barquero
Feb 7, 2008·The Journal of Clinical Psychiatry·Elaine H MorratoRobert J Valuck
Apr 9, 2008·Schizophrenia Research·Sarojini SenguptaRidha Joober
May 3, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Marisa Elena Domino, Marvin S Swartz
Jun 7, 2008·Schizophrenia Research·Jonathan M MeyerJeffrey A Lieberman
Jul 29, 2008·Bipolar Disorders·Antoni SicrasMilagrosa Blanca
Sep 9, 2008·Schizophrenia Research·Gail L DaumitJeffrey A Lieberman
Nov 11, 2008·Schizophrenia Research·Rocio Perez-IglesiasBenedicto Crespo-Facorro
Jan 17, 2009·The American Journal of Psychiatry·Dan W HauptJohn W Newcomer
Feb 27, 2009·Diabetes Care·Elaine H MorratoBrian Cuffel
Jun 6, 2009·The Journal of Clinical Psychiatry·Swapna K VermaLye Yin Poon
Jul 11, 2009·The Journal of Clinical Psychiatry·John W Newcomer
Jul 30, 2009·Pharmacotherapy·Mark E SchneiderhanCherise Rosen
Jan 6, 2010·Archives of General Psychiatry·Elaine H MorratoJohn W Newcomer
Citations
Feb 27, 2016·Journal of Clinical Pharmacy and Therapeutics·J LeeJ R Bostwick
Jan 21, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·A VentriglioA Bellomo
Sep 25, 2014·World Journal of Psychiatry·Pablo RichlyMarcelo Cetkovich-Bakmas